For questions regarding the Interface Map, please contact interface.support@aruplab.com.
Recommendations when to order or not order the test. May include related or preferred tests.
Secondary screening for systemic lupus erythematosus (SLE) based on ANA results.
Indicates whether a test has been approved by the New York State Department of Health.
This test is New York state approved.
Patient Preparation Instructions patient must follow before/during specimen collection.
Collect Specimen type to collect. May include collection media, tubes, kits, etc.
Serum separator tube.
Specimen Preparation Instructions for specimen prep before/after collection and prior to transport.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Storage/Transport Temperature Preferred temperatures for storage prior to and during shipping to ARUP. See Stability for additional info.
Unacceptable Conditions Common conditions under which a specimen will be rejected.
Plasma. Cerebral spinal fluid. Contaminated, hemolyzed, or severely lipemic specimens.
Remarks Additional specimen collection, transport, or test submission information.
Stability Acceptable times/temperatures for specimens. Times include storage and transport time to ARUP.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month (avoid repeated freeze/thaw cycles)
Process(es) used to perform the test.
Semi-Quantitative Indirect Fluorescent Antibody (IFA)
Days of the week the test is performed.
Expected turnaround time for a result, beginning when ARUP has received the specimen.
Normal range/expected value(s) for a specific disease state. May also include abnormal ranges.
May include disease information, patient result explanation, recommendations, or details of testing.
Positivity for anti-double stranded DNA (anti-dsDNA) IgG antibody is a diagnostic criterion of systemic lupus erythematosus (SLE). The presence of the anti-dsDNA IgG antibody is identified by IFA titer (Crithidia luciliae indirect fluorescent test [CLIFT]). CLIFT is highly specific for SLE with a sensitivity of 50-60 percent.
Some patients with early or inactive SLE may be positive for anti-dsDNA IgG by ELISA but negative by CLIFT. If the CLIFT result is negative but the patient has a positive ELISA and clinical suspicion remains, consider antinuclear antibody (ANA) testing by IFA. Additional information and recommendations for testing may be found at https://arupconsult.com/content/connective-tissue-diseases.
Compliance Category
Additional information related to the test.
Double Stranded DNA (dsDNA) antibodies (1:10 or greater) are found in 50-60 percent of systemic lupus erythematosus (SLE), 20-30 percent in Sjögren syndrome, 20-25 percent in mixed connective tissue disease (MCTD), and less than 5 percent in progressive systemic sclerosis (PSS). High titers of antibody to native (double stranded) DNA are specific for SLE.
The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually.
CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ.
CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
Components of test
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2002692 | Double-Stranded DNA (dsDNA) Ab IgG IFA | 58466-4 |
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Other names that describe the test. Synonyms.
